Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and outcome of congenital mesoblastic nephroma: A report of 376 patients registered in the SIOP 93-01, SIOP WT 2001, UK-IMPORT, and AIEOP protocols.

PloS one·2026
Same author

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Nature·2026
Same author

NKX2-1 regulates cell survival, maturation, and DNAdamage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.

Haematologica·2026
Same author

Optical Genome Mapping Is a Powerful Diagnostic Tool in Non-Hodgkin Lymphoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025
Same author

Xq24/<i>IL13RA1</i> aberrations as key drivers of female bias in primary mediastinal large B-cell lymphoma.

HemaSphere·2025
Same author

DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia.

Cancer chemotherapy and pharmacology·2025

Related Experiment Video

Updated: Oct 4, 2025

Optimized Workflow for Iterative Bleaching Extends Multiplexity Imaging of Highly Autofluorescent Clinical Samples
06:52

Optimized Workflow for Iterative Bleaching Extends Multiplexity Imaging of Highly Autofluorescent Clinical Samples

Published on: July 11, 2025

297

Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping.

Katrina Rack1, Jolien De Bie1,2, Geneviève Ameye1

  • 1Laboratory for the Cytogenetic and Molecular Diagnosis of Hematological Malignancies, Centre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.

American Journal of Hematology
|February 4, 2022
PubMed
Summary

Optical genome mapping (OGM) improves acute lymphoblastic leukemia (ALL) diagnostics by detecting more genomic alterations than standard methods. This advanced technique enhances patient stratification and treatment accuracy, reducing diagnostic time.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Related Experiment Videos

Last Updated: Oct 4, 2025

Optimized Workflow for Iterative Bleaching Extends Multiplexity Imaging of Highly Autofluorescent Clinical Samples
06:52

Optimized Workflow for Iterative Bleaching Extends Multiplexity Imaging of Highly Autofluorescent Clinical Samples

Published on: July 11, 2025

297
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Area of Science:

  • Genomics
  • Oncology
  • Molecular Diagnostics

Background:

  • Acute lymphoblastic leukemia (ALL) diagnosis relies on complex, time-consuming methods like chromosome banding analysis (CBA) and FISH.
  • Current diagnostic pathways for ALL are labor-intensive, costly, and may miss critical genomic alterations such as structural variants (SVs) and copy number alterations (CNAs).

Discussion:

  • Optical genome mapping (OGM) offers a single-test solution for detecting SVs and CNAs, streamlining ALL diagnostics.
  • OGM identified all recurrent CNAs and SVs, including additional recurrent SVs and fusion genes, in 41 ALL cases, surpassing standard methods.
  • The study demonstrated OGM's superior ability to assign patients to cytogenetic risk groups, identifying more chromosomal abnormalities than the standard approach.

Key Insights:

  • OGM significantly increased the detection rate and cytogenetic resolution for ALL, identifying 33/34 recurrent chromosomal abnormalities compared to 24/34 with standard methods.
  • OGM abrogated the need for cascade testing, leading to reduced diagnostic turnaround times and improved opportunities for patient stratification and treatment.
  • Excellent concordance was observed between OGM and existing methods like MLPA, validating OGM's reliability in ALL diagnostics.

Outlook:

  • While OGM shows promise, comprehensive cytogenomic testing may still require complementary methods like CBA or SNP-array for ploidy changes and BCR::ABL1 FISH for rapid targeted therapy assignment.
  • Further integration of OGM into routine ALL diagnostics could lead to more personalized treatment strategies and improved patient outcomes.
  • Continued research and validation are essential to fully leverage OGM's potential in hematologic malignancies.